Directorate General of Drug Administration (DGDA), Bangladesh

What Directorate General of Drug Administration (DGDA), Bangladesh does

Directorate General of Drug Administration (DGDA) is the national drug regulatory authority of Bangladesh, operating as a statutory directorate under the Ministry of Health and Family Welfare. DGDA holds exclusive statutory authority over the licensing, registration, market authorization, and surveillance of all pharmaceuticals (allopathic, biological, Ayurvedic, and Unani), vaccines, biosimilars, medical devices, cosmetics, and dietary supplements in Bangladesh. It regulates the country's manufacturing, import/export, distribution, and retail operations for these products, conducts GMP/GDP inspections, issues import/export certificates and NOCs, and exercises enforcement powers including license suspension and cancellation. The organization is headquartered in Mohakhali, Dhaka, with divisional and regional offices extending its reach nationwide, and operates under the legal framework of the Drugs and Cosmetics Act 2023.

DGDA delivers its services through an integrated digital platform stack comprising four principal online systems: ADLRS (Automated Drug Licensing and Registration System) for drug license applications and renewals; DGDA-RIMS for vaccine and biosimilar registration; PViMS (Pharmacovigilance Reporting System) for adverse drug reaction reporting; and the NRA Information System for regulatory information management. The National Drug Control Laboratory (NCL), an operating arm of DGDA, holds WHO Pre-Qualification certification and ISO ANAB accreditation, enabling it to conduct internationally recognized quality testing for the government and for WHO procurement agencies. DGDA also operates a Pharmacovigilance Centre, a market surveillance wing, a clinical trial oversight function, and an Antimicrobial Resistance surveillance program integrated with the National AMU Surveillance System. Import/export regulatory services are coordinated through integration with the Bangladesh Single Window (BSW) for customs processing.

DGDA's revenue model is dual and non-commercial: it collects regulatory fees for licenses, registrations, and laboratory testing services at government-determined rates, and receives annual budget allocations from the Government of Bangladesh through the Ministry of Health and Family Welfare. Its customer base spans the entire regulated pharmaceutical value chain — local manufacturers (across allopathic, biological, Ayurvedic, and Unani segments), pharmaceutical importers and exporters requiring NOCs and customs clearance, retail and wholesale pharmacies, clinical trial sponsors and CROs, vaccine manufacturers and suppliers, and medical device importers. The organization is led by a Director General (currently Moha: Alamgir Hossain in additional charge) reporting to the Ministry's Secretary of Health Services Division.

Name

Directorate General of Drug Administration (DGDA), Bangladesh

Legal name

Directorate General of Drug Administration (DGDA), Bangladesh

Website

https://dgda.gov.bd

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

DGDA is Bangladesh's national drug regulatory authority under the Ministry of Health and Family Welfare, licensing, registering, and surveilling pharmaceuticals, vaccines, biosimilars, medical devices, cosmetics, and dietary supplements across the country.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulation

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industry

Controlled Substances & Narcotics Regulators (HLAJADAK)

Keywords

• Drug regulation services
• Pharmaceutical licensing
• Pharmacovigilance monitoring
• Drug quality testing
• Regulatory compliance

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Regulatory Fees and Licenses: DGDA collects fees for drug manufacturing licenses, import/export licenses, drug registrations, test fees for the National Drug Control Laboratory, and various regulatory certifications. These fees support regulatory operations.
2. Government Budget Allocation: As a government directorate under the Ministry of Health and Family Welfare, DGDA is funded through annual government budgetary allocations.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

DGDA is Bangladesh's national drug regulatory authority operating under the Ministry of Health and Family Welfare. It issues drug manufacturing, retail/wholesale, export, and research-purpose licenses for allopathic, biological, Ayurvedic, and Unani medicines. It conducts drug registration and market authorization, operates the WHO-prequalified National Drug Control Laboratory for quality testing, performs GMP inspections and market surveillance, runs pharmacovigilance/ADR monitoring, oversees clinical trials, and regulates medical devices, vaccines, cosmetics, and dietary supplements.

Product overview

The Directorate General of Drug Administration (DGDA), Bangladesh is the national regulatory authority for pharmaceutical products. It operates as a comprehensive regulatory platform providing multiple interconnected services including drug manufacturing and distribution licensing (for allopathic, biological, Ayurvedic, and Unani medicines), drug registration and marketing authorization, quality testing through the National Drug Control Laboratory (NCL), market surveillance and enforcement, pharmacovigilance monitoring, clinical trial oversight, medical device regulation, and antimicrobial resistance surveillance. DGDA offers both digital online portals (ADLRS for licenses, RIMS for vaccines/biosimilars, PViMS for adverse reactions) and traditional paper-based services through its various forms and guidelines. The organization operates under the Ministry of Health and Family Welfare, implementing national drug policies and ensuring compliance with the Drugs and Cosmetics Act 2023.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Manufacturing License (Non-Biological/Allopathic)
• Biological/Vaccine Drug Manufacturing License
• Retail/Wholesale Drug License (Form 7)
• Drug Export License (Form 10A)
• Research Drug Manufacturing License (Form 17)
• Drug Registration and Marketing Authorization
• National Drug Control Laboratory (NCL) Testing Services
• Pharmacovigilance and Adverse Drug Reaction Monitoring
• GMP Inspections and Regulatory Compliance Audits
• Clinical Trial Authorization and Oversight
• Medical Device Registration and Import Regulation
• Antimicrobial Resistance (AMR) Surveillance
• Drug and Vaccine Recall Services

Named customers6 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO provides regulatory guidelines, pre-qualification programs, and technical assistance for drug regulation. DGDA adopts WHO guidelines including TRS guidelines for Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), Good Pharmacovigilance Practice (GVP), and guidelines for temperature-sensitive pharmaceutical products storage and transportation.
• Bangladesh Single Window (BSW)coreTechnology or IntegrationIntegration with Bangladesh Single Window enables pharmaceutical importers and exporters to submit regulatory documents and obtain clearances through a unified platform for customs processing. DGDA connects with BSW for import/export license verification.
• National AMU Surveillance SystemcoreTechnology or IntegrationDGDA participates in the National Antimicrobial (AMU) Surveillance System to monitor antimicrobial usage patterns and combat antimicrobial resistance (AMR) in Bangladesh. The organization publishes AMR bulletins and awareness materials.
• PViMS (Pharmacovigilance Monitoring System)coreTechnology or IntegrationPViMS is the online pharmacovigilance reporting system used by DGDA for collecting and analyzing adverse drug reaction reports. Healthcare professionals and pharmaceutical companies report adverse events through this system for post-market safety monitoring.
• DGDA-RIMS (Regulatory Information Management System)coreTechnology or IntegrationDGDA-RIMS is the regulatory platform for vaccine and biosimilar registration applications, enabling pharmaceutical companies to submit product registration documents and track application status online.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• European Medicines Agency (EMA): EU-wide drug regulator handling marketing authorization, pharmacovigilance, and GMP inspections across member states. Comparable in regulatory function to DGDA but with regional (rather than national) jurisdiction and far broader recognition.
• UK Medicines and Healthcare products Regulatory Agency (MHRA): UK's national regulator for medicines, medical devices, and blood components. Performs the same core functions as DGDA — licensing, registration, GMP inspections, pharmacovigilance, enforcement — with mature digital infrastructure and post-Brexit global ambition.
• U.S. Food and Drug Administration (FDA): The U.S. national drug and medical device regulator. Directly comparable in statutory role (licensing, GMP inspections, registration, pharmacovigilance, enforcement) to DGDA, but operates at vastly greater scale and with global recognition. The benchmark for any national drug regulator.

Direct peers

• Egyptian Drug Authority (EDA): Egypt's national drug regulator. Has visited DGDA's NCL for inspection/benchmarking (per DGDA website galleries), confirming direct comparability in lab quality standards and regulatory mandate.
• National Medicines Regulatory Authority (NMRA), Sri Lanka: Sri Lanka's national drug regulator. Comparable in function (drug registration, GMP inspections, pharmacovigilance) and similar in maturity stage to DGDA, serving a smaller South Asian market.
• Drug Regulatory Authority of Pakistan (DRAP): Pakistan's federal drug regulator responsible for licensing, registration, GMP inspections, and pharmacovigilance. Direct regional peer to DGDA serving a comparable pharmaceutical industry in a neighbouring South Asian country with similar regulatory maturity challenges.
• National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria: Nigeria's national regulator for food, drugs, cosmetics, and medical devices. Comparable in mandate scope, emerging-market regulatory context, and active enforcement profile to DGDA.
• Central Drugs Standard Control Organisation (CDSCO), India: India's national drug regulatory authority under the Ministry of Health. Closest direct peer to DGDA in scope and regional context — drug licensing, registration, clinical trial oversight, GMP inspections across a similarly large and rapidly growing pharmaceutical industry.
• Department of Drug Administration (DDA), Nepal: Nepal's national drug regulatory authority. Functions include drug registration, licensing, and quality control — directly comparable to DGDA's mandate. Nepal's NCL has previously visited DGDA's NCL for benchmarking, confirming direct comparability.

Others

• World Health Organization (WHO) Prequalification Team: WHO's Prequalification programme sets standards that DGDA's NCL has adopted and been certified against. While not a national regulator, WHO PQ is a direct partner and de facto benchmark authority shaping DGDA's lab and inspection standards.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/directorate-general-of-drug-administration-dgda-government-of-the-people-s-republic-of-bangladesh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Directorate General of Drug Administration (DGDA), Bangladesh